Literature DB >> 1486973

Nosocomial pneumonia in critically ill comatose patients: need for a differential therapeutic approach.

J Rello1, V Ausina, M Ricart, C Puzo, A Net, G Prats.   

Abstract

The purpose of this prospective clinical study was to determine the incidence, bacteriology and outcome of lower respiratory tract infections developed among 208 consecutive, critically ill comatose patients, hospitalized in a university hospital, medical-surgical intensive care unit, over a three year period. Nosocomial pneumonia developed in 53 (25%) patients after a mean of 8.1 days (range 3-31 days). Furthermore, there were five superinfections, raising the mean incidence to 28%. One patient developed secondary bacteraemia, and another two had septic shock. Fifteen (28%) patients from the pneumonia group died, and six of these deaths were considered to be directly related to nosocomial pneumonia. Identification of the causative agent, using the protected specimen brush technique, was possible in 42 episodes; in 10 (24%) of these cases more than one microorganism was isolated. Gram-positive cocci represented 53% of isolates, and Staphylococcus aureus accounted for 78% of all Gram-positive cocci, being the most frequent microorganism in this population. In conclusion, nosocomial pneumonia is a common complication of critically ill comatose patients. Its characteristic aetiological spectrum in this population should affect antibiotic prescription. Consequently, we suggest including antimicrobial drugs which are active against S. aureus in the empirical regimen until aetiological diagnosis is established.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486973

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

Review 1.  Prevention of nosocomial bacterial pneumonia.

Authors:  J L Vincent
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

2.  Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barré syndrome.

Authors:  David Orlikowski; Tarek Sharshar; Raphael Porcher; Djillali Annane; Jean Claude Raphael; Bernard Clair
Journal:  Intensive Care Med       Date:  2006-09-21       Impact factor: 17.440

3.  Retrospective analysis of risk factors and prognosis in non-ventilated patients with nosocomial pneumonia.

Authors:  J Gómez; A Esquinas; M D Agudo; J M Sánchez Nieto; M L Núñez; V Baños; M Canteras; M Valdes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

4.  Ventilator-associated pneumonia in severe traumatic brain injury.

Authors:  David A Zygun; Danny J Zuege; Paul J E Boiteau; Kevin B Laupland; Elizabeth A Henderson; John B Kortbeek; Christopher J Doig
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

5.  Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study.

Authors:  A Acquarolo; T Urli; G Perone; C Giannotti; A Candiani; N Latronico
Journal:  Intensive Care Med       Date:  2005-03-08       Impact factor: 17.440

6.  Unusually High Incidences of Staphylococcus aureus Infection within Studies of Ventilator Associated Pneumonia Prevention Using Topical Antibiotics: Benchmarking the Evidence Base.

Authors:  James C Hurley
Journal:  Microorganisms       Date:  2018-01-04

7.  Twenty-Eight-Day Mortality of Blunt Traumatic Brain Injury and Co-Injuries Requiring Mechanical Ventilation.

Authors:  Bojan Jovanovic; Zoka Milan; Olivera Djuric; Ljiljana Markovic-Denic; Aleksandar Karamarkovic; Pavle Gregoric; Krstina Doklestic; Jovana Avramovic; Jelena Velickovic; Vesna Bumbasirevic
Journal:  Med Princ Pract       Date:  2016-07-07       Impact factor: 1.927

8.  Incidence, temporal trend and factors associated with ventilator-associated pneumonia in mainland China: a systematic review and meta-analysis.

Authors:  Chengyi Ding; Yuelun Zhang; Zhirong Yang; Jing Wang; Aoming Jin; Weiwei Wang; Ru Chen; Siyan Zhan
Journal:  BMC Infect Dis       Date:  2017-07-04       Impact factor: 3.090

9.  Prevention of early ventilation-acquired pneumonia (VAP) in comatose brain-injured patients by a single dose of ceftriaxone: PROPHY-VAP study protocol, a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Claire Dahyot-Fizelier; Denis Frasca; Sigismond Lasocki; Karim Asehnoune; Dorothée Balayn; Anne-Laure Guerin; Pierre-François Perrigault; Thomas Geeraerts; Philippe Seguin; Bertrand Rozec; Djilali Elaroussi; Vincent Cottenceau; Clément Guyonnaud; Olivier Mimoz
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.